Skip to content

The genomic landscape of pulmonary lymphoepithelioma-like carcinoma

The genomic landscape of pulmonary lymphoepithelioma-like carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045454
Enrollment
Unknown
Registered
2021-04-15
Start date
2021-04-14
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary pulmonary lymphoepithelioma-like carcinoma

Interventions

Primary pulmonary lymphoepithelioma-like carcinoma:Nil

Sponsors

The First Affiliated Hospital ofGuangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. It is pathologically diagnosed as PLELC; 2. Immunohistochemistry or in situ hybridization of EBV coding RNAs (EBRAs) are positive; 3. Nasopharyngoscopy or CT or MRI of the Nasopharynx to rule out Nasopharyngeal carcinoma lung metastasis; 4. There are pathological tissue specimens, and there are enough tumor cells in the extracted pathological sections; 5. The PS score is evaluated according to the physical status score of the Eastern Tumor Collaborative Organization of the United States, PS 0-2;

Exclusion criteria

Exclusion criteria: 1. Incomplete clinical data and/or follow-up data; 2. Combined with other malignant tumors or mixed with other types of lung cancer; 3. Those who do not want to participate.

Design outcomes

Primary

MeasureTime frame
genomic mutation data;

Countries

China

Contacts

Public ContactBai Jing

The First Affiliated Hospital of Guangxi Medical University

bj1312002@aliyun.com+86 18978919881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026